Xenon Pharmaceuticals Inc.

Discovery, development and commercialisation of innovative medicines based on genetically derived targets.

Privately held company located in Vancouver.

Simon Pimstone, PhD, MD, President & CEO
Michael Hayden, PhD, MD, CSO
Vijay Sondhi, CFO
Rajender Kamboj, Executive Vice President, Drug Discovery
Karen Corraini, General Counsel

Michael Tarnow, Chair
Charles Cohen, PhD
Michael Hayden, MD, PhD
Frank Holler, MBA
Chris Ehrlich, MBA
Simon Pimstone, MD, PhD,
Parag Saxena, MBA, B. Tech, M.S.
Gary Patou, MD
Mohammad Azab, MD, MBA
Evan A. Stein, MD, PhD

3650 Gilmore Way
Burnaby, BC V5G 4W8
Canada
Phone: +1-604-484-3300
Fax: +1-604-484-3450

The company’s main programme is a small molecule treatment for obesity and metabolic syndrome, which is expected to advance into clinical development in early 2005. Xenon’s CNS and iron metabolism drug programmes are currently in lead optimisation. The therapies are based on genetic causes of select metabolic, neurological and cardiovascular diseases. The integrated target and drug discovery platform of Xenon includes gene discovery and validation to compound screening, chemical compound libraries, assay development, high throughput screening (HTS), medicinal chemistry and in vivo drug testing clinical-based approach, Xenon has discovered 17 genes to date.
The obesity/metabolic syndrome programme is focused on the development of small molecule inhibitors of the key enzyme stearoyl-CoA desaturase-1 (“SCD1”). The focus of Xenon’s iron overload programme regards the development of a novel class of small molecule compounds to reduce body iron stores for the treatment of iron overload disorders such as hemochromatosis and thalassaemia. Xenon’s HDL-cholesterol programme is focused on the development of small molecule compounds that will raise HDL-cholesterol. This programme is based primarily on the discovery of the ABCA1 gene as a major regulator of reverse cholesterol transport and HDL levels. Xenon also runs a neuroscience programme.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.